Nurix Therapeutics, Inc. $NRIX Shares Purchased by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 83.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,389,274 shares of the company’s stock after purchasing an additional 633,304 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 1.82% of Nurix Therapeutics worth $15,796,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Jump Financial LLC grew its position in shares of Nurix Therapeutics by 1.9% in the 1st quarter. Jump Financial LLC now owns 76,060 shares of the company’s stock valued at $904,000 after buying an additional 1,441 shares during the last quarter. Corebridge Financial Inc. grew its holdings in shares of Nurix Therapeutics by 5.6% during the first quarter. Corebridge Financial Inc. now owns 36,849 shares of the company’s stock worth $438,000 after purchasing an additional 1,942 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Nurix Therapeutics by 13.9% during the second quarter. Teacher Retirement System of Texas now owns 18,404 shares of the company’s stock worth $210,000 after purchasing an additional 2,248 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Nurix Therapeutics by 16.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 18,104 shares of the company’s stock valued at $206,000 after purchasing an additional 2,522 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after purchasing an additional 3,475 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Stifel Nicolaus set a $33.00 target price on shares of Nurix Therapeutics in a research report on Friday, October 10th. Truist Financial began coverage on shares of Nurix Therapeutics in a research report on Monday, November 24th. They issued a “buy” rating and a $30.00 price target for the company. Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $22.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, October 23rd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $19.07 on Friday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -6.42 and a beta of 1.87. The company’s fifty day moving average is $13.63 and its two-hundred day moving average is $11.74. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.19). The firm had revenue of $7.89 million during the quarter, compared to analyst estimates of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,284 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. This represents a 14.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 4,087 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $12.80, for a total value of $52,313.60. Following the completion of the sale, the insider owned 76,751 shares in the company, valued at approximately $982,412.80. This trade represents a 5.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 13,501 shares of company stock valued at $171,305. 7.40% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.